America’s Unsafe Medical Products

Print Email

Robotically Assisted Surgical Devices for Mastectomy Procedures
> Issue date: February 28, 2019
> Type of alert: Safety communication

The FDA is informing health care providers and patients that the safety and effectiveness of these devices has not been established either for mastectomy procedures or cancer prevention: “There is limited, preliminary evidence that the use of robotically assisted surgical devices for treatment or prevention of cancers that primarily (breast) or exclusively (cervical) affect women may be associated with diminished long-term survival.”

Physio-Control LIFEPAK 15 Monitors/Defibrillators
> Issue date: February 27, 2019
> Type of alert: Recall

Physio-Control has recalled 8,164 monitor/defibrillators to update the system’s firmware. The device may lock up (blank monitor while power indicators are lighted and no response from the keypad and no device functions). This is a Class I recall, meaning that continued use of these devices may cause serious injury or even death.

Golean Detox Capsules
> Issue date: February 25, 2019
> Type of Alert: Recall

Golean Detox USA voluntarily has issued a recall of all lots of its capsules following an FDA analysis that the capsules are tainted with substances that have been withdrawn by the agency from the U.S. market. The company said it has received no reports of adverse effects related to the recall.

Macleod’s Pharmaceuticals Losartan 100mg/25mg Tablets
> Issue date: February 25, 2019
> Type of Alert: Recall

The company is voluntarily recalling of two types of losartan tablets used to treat hypertension. One lot of losartan potassium and hydrochlorothiazide tablets has been found to have trace amounts of an unexpected carcinogen in tablets manufactured by Hetero Labs. The company has received no reports of adverse events related to this recall.

Pfizer Xeljanz and Xeljanz XR
> Issue date: February 25, 2019
> Type of Alert: Safety alert

The FDA is alerting patients, health care professionals, pharmacists and rheumatologist that Pfizer’s Xeljanz and Xeljanz XR increase the risk of blood clots in the lungs and death for patients with rheumatoid arthritis taking a twice-daily 10mg dose of the drug.

Total Thermal Imaging Inc. (TTI) Thermography Business Package
> Issue date: February 25, 2019
> Type of Alert: Warning

TTI has failed to take promised steps to replace misleading marketing messages for its thermography package. The company has mischaracterized the product as a stand-alone screening device for diagnosing breast cancer. The FDA has approved thermography only for use with another diagnostic tool. TTI faces severe sanctions if it fails to respond within 15 days to the FDA’s warning letter.

ICU Medical’s 20mm ChemoLock Vial Spike
> Issue date: February 25, 2019
> Type of alert: Recall

The company is recalling 2,050 units of its CL-80S ChemoLock Vial Spike due to the potential for plastic particles to break off the protective cap, potentially entering the drug delivery system and infused into a patient’s intravenous line resulting in “serious injury or death.” ICU Medical has received no reports of adverse effects related to this issue. The devices are commonly used in pharmacies that compound their own medicines and by health care facilities.